Creating new therapies using viruses to fight harmful bacteria and fungi.
Development of novel bacteriophage-based therapies to combat Pseudomonas aeruginosa and Candida spp. dual-species biofilms.
This study is exploring new ways to treat tough infections caused by bacteria and fungi that form protective barriers, using a combination of special viruses and natural proteins, so that patients can have better options for getting rid of these stubborn infections.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-10826662 on NIH RePORTER |
What this research studies
This research focuses on developing innovative treatments for infections caused by Pseudomonas aeruginosa and Candida species, which often form protective biofilms. The approach combines bacteriophage therapy, which uses viruses that target bacteria, with antimicrobial peptides to tackle both bacterial and fungal infections. By targeting dual-species biofilms, the research aims to enhance treatment effectiveness against these resistant pathogens. Patients may benefit from new therapies that could be more effective than current options.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with infections caused by Pseudomonas aeruginosa and Candida species, particularly those with mixed-species biofilm infections.
Not a fit: Patients with infections caused solely by non-target pathogens or those who do not have biofilm-related infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients suffering from difficult-to-treat infections caused by resistant bacteria and fungi.
How similar studies have performed: Previous research has shown promise in using bacteriophage therapy for bacterial infections, but the combination with antimicrobial peptides for dual-species biofilms is a novel approach.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Lam, Charlton — Ohio State University
- Study coordinator: Lam, Charlton
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.